James R. Tyminski practices intellectual property law with a particular focus on Hatch-Waxman patent litigation. Jim has extensive experience litigating patents covering polymorphic and solvated forms of active pharmaceutical ingredients.
He has also defended various patents covering novel pharmaceutical formulations, in particular oral and topical dosage forms.
While in law school, Jim served as an associate editor of the Baylor Law Review and was a member of Baylor’s moot court team. He also interned with Judge Mary Murphy of the 14th District Court in Dallas, TX.
At Rutgers University, Jim worked in Dr. Eddy Arnold’s laboratory at the Center for Advanced Biotechnology and Medicines. His undergraduate research and senior thesis focused on crystallization and structure determination of human capping enzyme and antiretroviral drugs, which led to a published article in Proceedings of the National Academy of Sciences.
Sanofi and Sanofi-Aventis U.S. LLC against Sun Pharmaceuticals on patents covering Plavix® (clopidogrel), an antiplatelet agent
LEO Pharma A/S against Tolmar and Perrigo regarding patents covering Dovonex® and Taclonex®, topical treatments for psoriasis
Sanofi and Sanofi-Aventis U.S. LLC against Glenmark, Watson, and others regarding patents covering Multaq®, an antiarrhythmic drug